My ePortfolio Register   

ESMO 2017 /
Small node-negative breast cancers may retain aggressive characteristics

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 391
Rating:

Dr Konstantinos Tryfonidis - European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium

Dr Tryfonidis speaks with ecancer at ESMO 2017 about the aggressive hallmarks identified in even small breast tumours.

These findings come from a subgroup of MINDACT patients whose tumours were ranked as both low and high risk by MammaPrint and Adjuvant! Online, respectively - this discordance led to randomised treatment based on either risk.

Based on 5 year distant metastasis-free survival, Dr Tryfonidis reports that patients who were treated with chemotherapy based on their MammaPrint risk score derived a survival benefit.

Read more about this story here.


ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence